Latest Sirolimus Stories
HONG KONG, Dec.
DURHAM, N.C., Nov. 29, 2010 /PRNewswire/ -- Micell Technologies,(TM) Inc.
HONG KONG, Nov.
NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
EAST HANOVER, N.J., Nov.
SILVER SPRING, Md., Oct. 30 /PRNewswire/ -- The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA).
EAST HANOVER, N.J., Oct. 29 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the U.S.
WOONSOCKET, R.I., Oct. 19 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc.
HONG KONG, Oct.
WATERLOO, Belgium, September 30, 2010 /PRNewswire/ -- - SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Clinical Safety and Efficacy Measures With Both CYPHER(R) Stent and XIENCE V(R) Stent - Only CYPHER Stent has More Than 10 years of Clinical Safety Data in 70 Studies Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary...
- A transitional zone between two communities containing the characteristic species of each.